Takeaways from 2020 Capital Markets Day
26/11/20 -"Novartis unveiled promising performance targets at its 2020 CMD. Besides striving for healthy top-line growth – driven by diverse innovations, the group also plans to improve operating margins – even ..."
Pages
65
Language
English
Published on
26/11/20
You may also be interested by these reports :
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...